Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Stephen
Aselage as President and Chief Operations Officer, effective
immediately. In his new role, Mr. Aselage will be responsible for
managing corporate development activities, including the
commercialization of existing products, building out the company’s
global infrastructure, and exploring new business development
opportunities.
“Steve has been a trusted advisor to Retrophin since our formation,
having served as a key member of our board of directors,” said Martin
Shkreli, Founder and CEO of Retrophin. “I have no doubt that the
expertise Steve has accumulated during his more than 30-year career in
the global pharmaceutical industry will be invaluable as we continue
advancing our pipeline of treatments for catastrophic diseases and
expanding our commercial product portfolio through strategic
transactions.”
“I’ve been impressed with Martin’s progress in building Retrophin over
the past year and a half,” said Mr. Aselage. “As President and Chief
Operations Officer, I look forward to sustaining this growth and helping
the company realize the full potential of its promising treatments for
rare and often life-threatening diseases.”
Prior to joining Retrophin in 2012, Mr. Aselage was Executive Vice
President and Chief Business Officer at BioMarin Pharmaceutical, Inc.
There, he built the commercial and medical affairs functions that
launched three commercial products and developed commercial business in
more than 45 countries.
Mr. Aselage has also held leadership roles with Sangstat Medical
Corporation and Genentech. He worked briefly for Genzyme, as well,
assisting in the transition following its acquisition of Sangstat.
Earlier in his career, he held a variety of sales and sales management
positions at companies including Rhone-Poulenc Rorer Pharmaceuticals
(now Sanofi-Aventis) and Bristol Laboratories. Mr. Aselage received his
B.S. in biology from the University of Notre Dame.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's marketed products include Chenodal®
and Vecamyl®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
schizophrenia, autism, infantile spasms, nephrotic syndrome and others.
Retrophin intends to reintroduce Syntocinon Nasal Spray in the U.S. to
assist initial postpartum milk ejection. For additional information,
please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. In addition, expressions of our strategies, intentions or
plans are also forward-looking statements. Such forward-looking
statements are based on current expectations and involve inherent risks
and uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can
be guaranteed. Forward-looking statements in the press release should be
evaluated together with the many uncertainties that affect the Company's
business. You are cautioned not to place undue reliance on these
forward-looking statements as there are important factors that could
cause actual results to differ materially from those in forward-looking
statements, many of which are beyond our control. The Company undertakes
no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise. Investors
are referred to the full discussion of risks and uncertainties as
included in the Company's filings with the Securities and Exchange
Commission.
Copyright Business Wire 2014